Compare VYGR & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | RNAC |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.0M | 214.8M |
| IPO Year | 2015 | 2016 |
| Metric | VYGR | RNAC |
|---|---|---|
| Price | $3.74 | $6.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $21.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 862.4K | 185.1K |
| Earning Date | 03-09-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,135,000.00 | $2,797,000.00 |
| Revenue This Year | $54.19 | N/A |
| Revenue Next Year | $20.22 | $26.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.65 | $5.98 |
| 52 Week High | $5.55 | $16.79 |
| Indicator | VYGR | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 42.39 |
| Support Level | $3.36 | $6.44 |
| Resistance Level | $3.74 | $8.10 |
| Average True Range (ATR) | 0.32 | 0.76 |
| MACD | -0.06 | -0.15 |
| Stochastic Oscillator | 4.87 | 9.79 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.